Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Opexa Hits Transfer Milestone with Novartis | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Opexa Hits Transfer Milestone with Novartis

Opexa achieved its first milestone in its stem cell pact with Novartis.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Opexa Therapeutics has achieved its first technology transfer milestone in connection with its recently announced exclusive stem cell agreement with Novartis. The milestone was completed on schedule and triggers a payment of $500,000 to Opexa.

Opexa recently entered into an exclusive agreement with Novartis for the further development of its novel stem cell technology. Opexa received an upfront cash payment of $3 million and was entitled to an additional $1 million as a technology transfer fee to be paid over the course of a six-month period. The $500,000 milestone is part of this $1 million fee. Total payments to Opexa, including the upfront payment, the technology transfer fee and development and commercial milestone payments could exceed $50 million, not including royalties. Opexa is eligible to receive royalty payments from the sale of any products resulting from the use of the technology and retains an option on certain manufacturing rights.

Opexa is developing Tovaxin, a personalized T-cell immunotherapy for multiple sclerosis (MS).

Read our profile on Novartis in this year’s Top Companies Report!

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters